Publications by authors named "S A Loening"
Rubin H. Flocks and colloidal gold treatments for prostate cancer.
ScientificWorldJournal
February 2012
In the early 1950s, Rubin H. Flocks of the University of Iowa began to treat prostate cancer patients with colloidal gold (Au(198)) therapy, evolving his technique over nearly 25 years in 1515 patients. We reviewed the long-term outcomes of Flocks' prostate cancer patients as compared to those patients treated by other methods at the University of Iowa before Flocks' chairmanship.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated how well TP53 mutations and PSA levels predict tumor progression in prostate cancer patients.
- In a sample of 90 patients, 35.6% had TP53 mutations, which were linked to higher rates of tumor progression compared to those without mutations.
- TP53 mutations in specific regions (exon 7 and exon 8) were found to be more significant indicators of tumor recurrence than other factors like tumor stage or initial PSA levels.
Objectives: Patients with metastatic papillary renal cell carcinoma (RCC) show special clinical behavior compared to patients with other histologic subtypes of RCC. This study aimed to assess the relevance of surgical and systemic options used in treatment of these patients prior to the recent era of targeted therapies.
Methods: Retrospectively, we assessed clinical data of 61 patients with metastatic papillary RCC who were treated at eight centers in Germany.
Partial segmental thrombosis of the corpus cavernosum is a rare disease of unknown etiology; the thrombosis is always located in the proximal part of the corpus cavernosum, usually unilaterally. Typical clinical presentation with perineal pain and swelling in combination with cross-sectional imaging allows one to confidentially establish this diagnosis.
View Article and Find Full Text PDFAims: CD146 is a potentially metastasis promoting cell adhesion molecule and its expression has been described in various solid tumours. We aimed to evaluate the expression of CD146 in prostate cancer by immunohistochemistry in a clinically characterised study cohort to evaluate its prognostic properties.
Methods: We evaluated the CD146 protein expression using a polyclonal and a monoclonal antibody on 169 clinico-pathologically characterised cases.